YESCARTA® (axicabtagene ciloleucel)
A Gilead Company
This website is intended for healthcare professionals and will contain promotional information.
This website is sponsored by Kite, a Gilead company. Gilead Sciences Sweden AB | Hemvärnsgatan 9, 171 54 Solna | Tel: 08 505 71 800 Content generated on June 2nd, 2021, and last revised on November 29th, 2021. Market authorization holder: Kite Pharma EU B.V., Tufsteen 1, 2132 NT Hoofddorp, The Netherlands. This web page is intended to give an overview of the stages of YESCARTA® treatment only. Please see to the European Medicines Agency website https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta for complete product information and the risk management plan summary for YESCARTA®. YESCARTA® (axicabtagene ciloleucel) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy.